Corona Remedies IPO: An Analysis
The Corona Remedies IPO is showing strong interest from investors. As of this morning, the IPO has been fully subscribed, meaning more people want to buy shares than the company is offering. This is particularly driven by non-investors, who are eagerly snapping up shares.
Key Points
- Over 50 times subscribed, driven primarily by non-institutional investors.
- Shares received bids for 229.5 million, a substantial oversubscription.
- Grey market premium of 25.5% reflects strong investor confidence.
- IPO offers 6.2 million shares priced between ₹1,008 and ₹1,062.
- Shares will be allotted on Thursday, with potential delivery by Dec 12.
- Expected listing on Dalal Street (BSE & NSE) on December 15.
The IPO is attracting investors because of a positive mood in the stock market. Investors are bidding on an average of 14.83 times their quota, showing strong confidence in the company’s future. This suggests that Corona Remedies is seen as a promising investment.
The IPO details are important for anyone considering investing. The offer includes 6.2 million shares, which are being sold at a price range of ₹1,008 to ₹1,062 per share. To buy one lot, investors need at least ₹14,868.
The company isn’t raising new funds through the IPO. Existing shareholders are selling their shares. This IPO is overseen by Bigshare Services, with JM Financial, IIFL Capital Services, and Kotak Mahindra Capital Company acting as the lead managers.
The timeline is key for investors. The final allotment decisions will be made on Thursday, and successful bidders should receive their shares by December 12th. The company is expected to officially start trading on Dalal Street on December 15th.
“A fully subscribed IPO signals strong market sentiment towards Corona Remedies’ prospects.”
